Akari Therapeutics Plc Files 2024 10-K
Ticker: AKTX · Form: 10-K · Filed: Apr 15, 2025 · CIK: 1541157
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financial-instruments, corporate-actions
Related Tickers: AKTX
TL;DR
AKTX 2024 10-K filed. Focus on pharma prep, warrants, and recent private placement. Check financials.
AI Summary
Akari Therapeutics Plc filed its 2024 10-K on April 15, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC, is involved in the pharmaceutical preparations industry. Key financial instruments mentioned include November Two Thousand Twenty Two Warrants and Series B Warrants, with financial data related to patents and domestic country operations. The filing also notes a private placement event on May 31, 2024, and a subsequent event on March 2, 2025.
Why It Matters
This filing provides a comprehensive overview of Akari Therapeutics' financial health and operational activities for the fiscal year 2024, including details on its financial instruments and strategic events.
Risk Assessment
Risk Level: medium — The company operates in the pharmaceutical sector, which is inherently risky due to R&D costs, regulatory hurdles, and market competition, as indicated by the mention of patents and various financial instruments.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
- 2025-04-15 — Filing Date (The date Akari Therapeutics Plc submitted its 10-K to the SEC.)
- 2023-12-31 — Prior Year End (Reference point for year-over-year comparison.)
- 2024-11-14 — PeakBio Event Date (Specific date related to PeakBio.)
- 2025-03-02 — Subsequent Event Date (Date of a significant event occurring after the fiscal year end.)
Key Players & Entities
- Akari Therapeutics Plc (company) — Filer
- Celsus Therapeutics Plc (company) — Former company name
- Morria Biopharmaceuticals PLC (company) — Former company name
- 2024-12-31 (date) — Period of report
- 2025-04-15 (date) — Filing date
- 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
- PeakBio (company) — Mentioned entity
- November Two Thousand Twenty Two Warrants (financial_instrument) — Financial instrument
- Series B Warrants (financial_instrument) — Financial instrument
- Dr Prudo And Dr Patel (person) — Mentioned individuals
FAQ
What is the primary business of Akari Therapeutics Plc?
Akari Therapeutics Plc is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code 2834.
What were the former names of Akari Therapeutics Plc?
Akari Therapeutics Plc was formerly known as Celsus Therapeutics Plc (name change on 2013-06-21) and Morria Biopharmaceuticals PLC (name change on 2012-02-01).
What specific financial instruments are mentioned in the filing?
The filing mentions November Two Thousand Twenty Two Warrants, Series B Warrants, Series C Warrants, and Two Thousand Twenty One Notes.
When did a significant subsequent event occur?
A significant subsequent event, a private placement, occurred on March 2, 2025.
What is the company's business address?
The company's business address is 22 Boston Wharf Road, Fl 7, Boston, MA 02210.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 15, 2025 by Dr Prudo And Dr Patel regarding Akari Therapeutics Plc (AKTX).